Schmoll, Hans-Joachim <br/><br/>
Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).  [electronic resource] 

 -  Journal of clinical oncology : official journal of the American Society of Clinical Oncology  Oct 2012 
 - 3588-95 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1527-7755 
<br/><br/><label>Standard No.: </label>10.1200/JCO.2012.42.5355  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antibodies, Monoclonal, Humanized--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Biopsy, Needle<br/>Colorectal Neoplasms--drug therapy<br/>Confidence Intervals<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Female<br/>Fluorouracil--therapeutic use<br/>Humans<br/>Immunohistochemistry<br/>Kaplan-Meier Estimate<br/>Leucovorin--therapeutic use<br/>Male<br/>Middle Aged<br/>Neoplasm Invasiveness--pathology<br/>Neoplasm Staging<br/>Organoplatinum Compounds--therapeutic use<br/>Patient Selection<br/>Proportional Hazards Models<br/>Quinazolines--therapeutic use<br/>Risk Assessment<br/>Survival Analysis<br/>Treatment Outcome<br/>Young Adult